The effects of probiotic supplementation for gastric cancer patients: A systematic review and meta-analysis of randomized controlled trials
In brief
Probiotics linked to 61% fewer postoperative complications in gastric cancer trials
A meta-analysis of 35 trials involving 2,792 patients found lower postoperative complication rates with probiotics, alongside changes in nutrition, immune markers and recovery. The evidence is uncertain: studies were all conducted in China, most were poor quality, and certainty was low or very low, so whether probiotics improve outcomes in broader practice remains unclear.
- Journal
- Clinical nutrition (Edinburgh, Scotland) (Q1)
- Published
- 6 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Tao Sun, Ruping Zhao, Haoran Qu, Xishen Shan, Yu Liu, Yuling Zheng
- PMID
- 43019878
- DOI
- 10.1016/j.clnu.2026.106844
Why clinicians should know about it
- Picked for Surgery (top studies of the week, 15 November 2026): Gastric cancer surgery, postoperative recovery, and complications
Abstract
BACKGROUND AND AIMS: Patients with gastric cancer often suffer from malnutrition, immunosuppression, and gut microbiota dysbiosis. This study aims to systematically evaluate the effects of probiotic supplementation on clinical outcomes in patients with gastric cancer. METHODS: A systematic search of 8 electronic databases was conducted to identify RCTs comparing the effects of probiotics versus standard care in gastric cancer patients. The ROB 2 was used to assess quality of RCTs. Stata 18 was employed to perform meta-analysis, subgroup analysis, meta-regression, sensitivity analysis, and publication bias analysis. The quality of evidence was graded using GRADE. RESULTS: A total of 34 studies (35 RCTs: 2792 patients) were included. The probiotic group showed improvements in serum protein levels (total protein: SMD = 1.25; albumin: SMD = 0.89), immune function parameters (CD3+%: SMD = 0.77; CD4+%: SMD = 1.32), gut microbiota (Bifidobacterium: SMD = 1.83; Lactobacillus: SMD = 1.84), inflammatory markers (CRP: SMD = -1.79; IL-6: SMD = -0.99), and postoperative recovery (time to first flatus: SMD = -1.36; length of hospital stay: SMD = -0.82). The probiotic group had lower rates of postoperative complications (RR = 0.39), gastrointestinal reactions (RR = 0.49), and loss of appetite (RR = 0.66). Heterogeneity was high for most outcome measures, and quality of evidence ranged from low to very low. CONCLUSION: Probiotic supplementation may be associated with positive changes in several short-term clinical outcomes and surrogate laboratory markers in patients with gastric cancer. However, all studies were conducted in China, most were of poor quality, and the certainty of GRADE evidence was generally low or very low. Therefore, these findings should be interpreted with caution. Future research requires more high-quality, multicenter RCTs with rigorous designs and standardized intervention protocols to further validate the clinical value of probiotics in patients with gastric cancer. REGISTRATION: PROSPERO registration number: CRD420261298426.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.